Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
0.71 AUD
35.64 M AUD
88.18 M AUD
39.70 M
About CLINUVEL PHARMACEUTICALS LIMITED
Sector
CEO
Philippe Jacques Wolgen
Headquarters
Melbourne
Website
Founded
1999
ISIN
AU000000CUV3
FIGI
BBG000C41KM7
Clinuvel Pharmaceuticals Ltd. operates as a biopharmaceutical company. The firm engages in the development of SCENESSE, its proprietary photoprotective drug. It also offers drugs for the treatment of various skin disorders. The company was founded by Robert Thomas Dorr on December 14, 1999 and is headquartered in Melbourne, Australia.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of CUV is 13.14 AUD — it has decreased by −0.15% in the past 24 hours. Watch CLINUVEL PHARMACEUTICALS LIMITED stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on ASX exchange CLINUVEL PHARMACEUTICALS LIMITED stocks are traded under the ticker CUV.
CUV stock has fallen by −3.03% compared to the previous week, the month change is a −4.78% fall, over the last year CLINUVEL PHARMACEUTICALS LIMITED has showed a −21.13% decrease.
We've gathered analysts' opinions on CLINUVEL PHARMACEUTICALS LIMITED future price: according to them, CUV price has a max estimate of 48.00 AUD and a min estimate of 17.00 AUD. Watch CUV chart and read a more detailed CLINUVEL PHARMACEUTICALS LIMITED stock forecast: see what analysts think of CLINUVEL PHARMACEUTICALS LIMITED and suggest that you do with its stocks.
CUV stock is 2.00% volatile and has beta coefficient of −0.44. Track CLINUVEL PHARMACEUTICALS LIMITED stock price on the chart and check out the list of the most volatile stocks — is CLINUVEL PHARMACEUTICALS LIMITED there?
Today CLINUVEL PHARMACEUTICALS LIMITED has the market capitalization of 670.81 M, it has decreased by −0.96% over the last week.
Yes, you can track CLINUVEL PHARMACEUTICALS LIMITED financials in yearly and quarterly reports right on TradingView.
CLINUVEL PHARMACEUTICALS LIMITED is going to release the next earnings report on Feb 25, 2025. Keep track of upcoming events with our Earnings Calendar.
CUV earnings for the last half-year are 0.49 AUD per share, whereas the estimation was 0.44 AUD, resulting in a 12.13% surprise. The estimated earnings for the next half-year are 0.21 AUD per share. See more details about CLINUVEL PHARMACEUTICALS LIMITED earnings.
CLINUVEL PHARMACEUTICALS LIMITED revenue for the last half-year amounts to 55.90 M AUD, despite the estimated figure of 54.88 M AUD. In the next half-year revenue is expected to reach 34.65 M AUD.
CUV net income for the last half-year is 24.70 M AUD, while the previous report showed 10.94 M AUD of net income which accounts for 125.86% change. Track more CLINUVEL PHARMACEUTICALS LIMITED financial stats to get the full picture.
Yes, CUV dividends are paid annually. The last dividend per share was 0.05 AUD. As of today, Dividend Yield (TTM)% is 0.37%. Tracking CLINUVEL PHARMACEUTICALS LIMITED dividends might help you take more informed decisions.
CLINUVEL PHARMACEUTICALS LIMITED dividend yield was 0.33% in 2024, and payout ratio reached 6.99%. The year before the numbers were 0.28% and 8.07% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. CLINUVEL PHARMACEUTICALS LIMITED EBITDA is 44.69 M AUD, and current EBITDA margin is 50.73%. See more stats in CLINUVEL PHARMACEUTICALS LIMITED financial statements.
Like other stocks, CUV shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade CLINUVEL PHARMACEUTICALS LIMITED stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So CLINUVEL PHARMACEUTICALS LIMITED technincal analysis shows the strong sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating CLINUVEL PHARMACEUTICALS LIMITED stock shows the sell signal. See more of CLINUVEL PHARMACEUTICALS LIMITED technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.